Evidence map›Paper›PMID 37921869›Full record

ReviewMedical oncology (Northwood, London, England)2023

Glucosinolates in cancer prevention and treatment: experimental and clinical evidence.

Neda Orouji, Siamak Kazemi Asl, Zahra Taghipour, Solomon Habtemariam, Seyed Mohammad Nabavi, Roja Rahimi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Neda OroujiDepartment of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, 1417653761, Iran.
Siamak Kazemi AslDeputy of Education, Ministry of Health and Medical Education, Tehran, Iran.
Zahra TaghipourDepartment of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, 1417653761, Iran.
Solomon HabtemariamPharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Chatham-Maritime, Kent, ME4 4TB, UK.
Seyed Mohammad NabaviPharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Chatham-Maritime, Kent, ME4 4TB, UK.
Roja RahimiDepartment of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, 1417653761, Iran. rojarahimi@gmail.com.ORCID http://orcid.org/0000-0001-8637-4350
Baqiyatallah University of Medical Sciences · IRTehran University of Medical Sciences · IRMinistry of Health and Medical Education · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucosinolates are naturally occurring β-d-thioglucosides that mainly exist in the Brassicaceae family. The enzyme myrosinase hydrolyzes glucosinolates to form isothiocyanates, which are chemical protectors. Phenethyl isothiocyanate, sulforaphane, and benzyl isothiocyanate are potential isothiocyanate with efficient anti-cancer effects as a protective or treatment agent. Glucosinolate metabolites exert the cancer-preventive activity through different mechanisms, including induction of the Nrf2 transcription factor, inhibition of expression of tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β), induction of apoptosis through inhibiting phase I enzymes and inducting phase II enzymes, interruption of caspase pathways, STAT1/STAT2, inhibition of sulfotransferases. Moreover, glucosinolates and their metabolites are effective in cancer treatment by inhibiting angiogenesis, upregulating natural killers, increasing expression of p53, p21, caspase 3 and 9, and modulating NF-κB. Despite the mentioned cancer-preventing effects, some isothiocyanates can increase the risk of tumors. So, further studies are needed to obtain an accurate and effective dose for each glucosinolates to treat different types of tumors.

Indexed as

BrassicaNeoplasmsGlucosinolatesHumansIsothiocyanatesNF-kappa BGlucosinolatesIsothiocyanatesNF-kappa BBroccoliCabbageCancerCruciferaeGlucosinolatesIsothiocyanateTumor

Identifiers

PMID37921869
OpenAlexW4388291187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.